Infections caused by Pseudomonas aeruginosa isolates in patients of Surgical Infections Department

Authors

  • O. M. Besedin Municipal institution «Dnipropetrovsk City Multidisciplinary Clinical Hospital № 4» DRC Dnipro, Ukraine, Ukraine
  • S. O. Kosulnikov Municipal institution «Dnipropetrovsk І. І Mechnikov Regional Clinical Hospital» Dnipro, Ukraine, Ukraine
  • L. M. Storubel Municipal institution «Dnipropetrovsk City Multidisciplinary Clinical Hospital № 4» DRC Dnipro, Ukraine, Ukraine
  • S. I. Karpenko State Institution «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine» Dnipro, Ukraine, Ukraine
  • S. O. Tarnopolsky Municipal institution «Dnipropetrovsk І. І Mechnikov Regional Clinical Hospital» Dnipro, Ukraine, Ukraine
  • K. V. Kravchenko Municipal institution «Dnipropetrovsk І. І Mechnikov Regional Clinical Hospital» Dnipro, Ukraine, Ukraine
  • A. S. Kudryavtsev Municipal institution «Dnipropetrovsk City Multidisciplinary Clinical Hospital № 4» DRC Dnipro, Ukraine, Ukraine
  • K. O. Sinitsa Municipal institution «Dnipropetrovsk City Multidisciplinary Clinical Hospital № 4» DRC Dnipro, Ukraine, Ukraine
  • G. M. Pundik Municipal institution «Dnipropetrovsk City Multidisciplinary Clinical Hospital № 4» DRC Dnipro, Ukraine, Ukraine
  • L. I. Karpenko Municipal institution «Dnipropetrovsk City Multidisciplinary Clinical Hospital № 4» DRC Dnipro, Ukraine, Ukraine

DOI:

https://doi.org/10.34287/MMT.2(41).2019.11

Abstract

The role of Pseudomonas aeruginosa isolates among the pathogens of surgical infection in purulent-septic surgery department for 2018 is determined. Investigated the antibiotic resistance of Pseudomonas aeruginosa hospital strains and the most effective antibiotics were investigated. Poly resistant in wound material were almost half of the cultures of Pseudomonas aeruginosa (19 strains, 45,2%). Carbapenem resistant Pseudomonas aeruginosa was found to be 47,1%. Of the aminoglycoside group antibiotics, Tobramycin (82,1%) showed the best sensitivity, Amikacin was sensitive in half of the microorganisms tested (55,0%). The sensitivity of cephalosporins ranged from 23,1% (Cefoperazone) to 40,5% (Ceftazidime). Even the use of the Sulbactam protective molecule did not improve the situation: 37,5% (Cefoperazone/ Sulbactam). For fluoroquinolones (Ciprofloxacin) sensitive third part of bacteria only. Piperacillin with Tazobactam, Fosfomycin, and Colistin E showed a high anti-pseudomonad efficacy. The use of anti-diarrhea bacteriophage was ineffective.

References

Global Action Plan to Combat Antimicrobial Resistance. Sixty-ninth World Health Assembly. Item 14.4 of the provisional agenda (A69/24 Add.1. Of May 13, 2016), http://apps.who.int/gb/ ebwha/pdf_files/WHA69/A69_24Add1-ru.pdf.

Talbot GH, Bradley J, Edwards JE Jr, Gilbert D et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42 (5): 657–668. DOI: 10.1086/499819.

Poole K. Pseudomonas aeruginosa: resistance to the max. Frontiersin Microbiology. 2011; 2: 65. DOI: 10.3389/fmicb.2011.00065.

Ministry of Health Protection of Ukraine. Order 05.04.2007 № 167. About the approval of the methodical instructions «Determination of microorganism sensitivity to antibacterial drugs», http://mozdocs.kiev.ua/view.php?id=6958.

The European Committee on Antimicrobial Susceptibility Testing – EUCAST. Tables of boundary values for the interpretation of the values of the IPC and the diameters of zones of growth inhibition. Version 8.0, 2018, http:// www.eucast.org.

Central Asian and Eastern European Surveillance of Antimicrobial Resistance. Annual report 2018, http://www.eucast.org.

Downloads

Published

2019-06-20

How to Cite

Besedin, O. M. ., Kosulnikov, S. O. ., Storubel, L. M. ., Karpenko, S. I. ., Tarnopolsky, S. O. ., Kravchenko, K. V. ., Kudryavtsev, A. S. ., Sinitsa, K. O. ., Pundik, G. M. ., & Karpenko, L. I. . (2019). Infections caused by Pseudomonas aeruginosa isolates in patients of Surgical Infections Department. Modern Medical Technology, (2), 56–60. https://doi.org/10.34287/MMT.2(41).2019.11

Issue

No. 2 (2019): Modern medical technology (part 1)

Section

Original research

License

The work is provided under the terms of the Public Offer and of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows an unlimited number of persons to reproduce and share the Licensed Material in all media and formats. Any use of the Licensed Material shall contain an identification of its Creator(s) and must be for non-commercial purposes only.